TG Therapeutics announced that enrollment has commenced in a pivotal Phase 3 trial evaluating a subcutaneous (SubQ) formulation of BRIUMVI (ublituximab-xiiy). This trial targets individuals with relapsing forms of multiple sclerosis (RMS).
The study is designed to assess two different subcutaneous dosing regimens: an every-other-month schedule and a quarterly schedule. This initiative aims to provide a more convenient, self-administered treatment option for patients.
BRIUMVI is currently approved in the United States and several international territories as a one-hour intravenous (IV) infusion. The development of a subcutaneous option is expected to broaden patient access and enhance the product's competitive profile by offering both IV and self-administered choices.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.